Biosimilar Suffixes Appear Superfluous In Adverse Event Reporting
Executive Summary
Nearly all adverse event reports received by US FDA include brand name of biosimilar, raising questions as to whether suffix on nonproprietary name is necessary for pharmacovigilance.
You may also be interested in...
Biosimilar Education Needed To Eliminate 'Nocebo' Effect, Pfizer Says
Material to help providers and patients understand scientific issues can inspire more confidence in the products, exec says.
New CDER No. 2 May Impact FDA's Safety Monitoring Aspirations
Patrizia Cavazzoni, CDER's new deputy director for operations, has safety surveillance background and wants to see FDA continue to grow its capabilities.
Novel Biologics Will Get Suffixes (Or At Least One Did)
US FDA's approval of Ultragenyx's Mepsevii (vestronidase alfa-vjbk) marks first novel biologic with a suffix, but 10 months after release of the naming guidance how – and even how widely – FDA will implement the policy remains uncertain.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Generics Bulletin?
Request a free trial today!
Register for our free email digests:
Register for our free email digests: